Get the Stockscreener App
3.21
2.88%
0.09
After Hours:
3.23
0.02
+0.62%
Evotec Se Adr stock is traded at $3.21, with a volume of 103.17K.
It is up +2.88% in the last 24 hours and up +38.96% over the past month.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
See More
Previous Close:
$3.12
Open:
$3.18
24h Volume:
103.17K
Relative Volume:
0.75
Market Cap:
$1.14B
Revenue:
$890.87M
Net Income/Loss:
$-115.85M
P/E Ratio:
-9.8436
EPS:
-0.3261
Net Cash Flow:
$-104.29M
1W Performance:
+19.33%
1M Performance:
+38.96%
6M Performance:
-18.32%
1Y Performance:
-4.75%
1-Day Range:
$3.16
$3.235
1-Week Range:
$2.59
$3.235
52-Week Range:
$2.308
$4.80
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
3.21 | 1.11B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-03-26 | Initiated | Berenberg | Buy |
| Apr-24-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com Australia
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Earnings call transcript: Evotec SE ADR Q4 2025 sees revenue growth, stock surges - Investing.com
Evotec sees weak 2026 outlook after in-line 2025 results, $100 mln deal By Investing.com - Investing.com South Africa
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal - Benzinga
Evotec's B2B Partner Search Initiative: Unlocking Strategic Collaborations in Drug Discovery for Nor - AD HOC NEWS
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 - ChartMill
Evotec appoints Ashiq Khan as chief commercial officer - Investing.com
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer - ChartMill
Evotec SE Stock: Drug Discovery Leader Faces Restructuring Challenges Ahead of Key Earnings - AD HOC NEWS
Evotec SE stock faces pressure amid biotech sector volatility and partnership updates - AD HOC NEWS
Evotec SE Stock Faces Pressure Amid Biotech Sector Headwinds and Pipeline Updates in Q1 2026 - AD HOC NEWS
JustEvotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses - ChartMill
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Evotec Aktie | DE0005664809 | ETR:EVT | News & Aktienkurs | FRA:EVT - LYNX Online Broker
Evotec shares surge 8% as Berenberg initiates with “buy” on partner value By Investing.com - Investing.com South Africa
Is Evotec SE (EVO) One of the Best Debt-Free Penny Stocks to Buy Right Now? - Finviz
Financial Review: Evotec (NASDAQ:EVO) & Savara (NASDAQ:SVRA) - Defense World
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations - Chartmill
Taxes of Evotec SE Sponsored ADR – LSX:A0QZ3J - TradingView — Track All Markets
EvotecHow Low A Company May Go While Still Being Attractive (NASDAQ:EVO) - Seeking Alpha
Evotec AG Earnings Call: Resilience Amidst Challenges - MSN
Evotec AG Reports Strategic Shift Amid Mixed Performance - MSN
Annual General Meeting - Evotec
Investor Relations - Evotec
Evotec shares tumble 9% as drug discovery segment weakens - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Should I buy Evotec (EVO) - zacks.com
ETFs Investing in Evotec SE Sponsored ADR Stocks - TradingView
Stock Information - Evotec
Evotec SE ADR earnings missed by $0.07, revenue fell short of estimates - Investing.com Australia
Evotec AG Reports Mixed H1 2025 Performance - TipRanks
Evotec and Sandoz plan potential sale of Toulouse biologics site - Investing.com
Evotec stock tumbles after slashing 2025 revenue guidance By Investing.com - Investing.com UK
EVT Stock Price and Chart — XETR:EVT - TradingView
Evotec SE ADR earnings beat by $0.08, revenue topped estimates - Investing.com UK
Evotec SE Reports Strong Q4 2024 and New Strategy - TipRanks
The integrin repertoire drives YAP-dependent epithelial:stromal interactions during injury of the kidney glomerulus - Nature
Evotec SE Sponsored ADR Trade Ideas — LSX:A0QZ3J - TradingView — Track All Markets
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):